2 news items
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
MRVI
18 Apr 24
for an unmatched partner," shared Drew Burch, President of Nucleic Acid Production. "This new facility codifies our commitment to advancing the field by playing
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
DYAI
MRVI
13 Feb 24
products. To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster
- Prev
- 1
- Next